Bioresorbable vascular scaffolds were developed to overcome the problems of drug eluting stents in percutaneous coronary intervention (PCI). This article reports the observations made in the study which compared an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent in the routine PCI. Drug eluting stents have been part of the standard care in percutaneous coronary intervention (PCI). However, their rigid metallic cages hamper the vasomotion, and they are reported to develop neo-atherosclerosis, which increases the risk of stent thrombosis and repeat vascularization.
Whereas, bioresorbable scaffolds leave no permanent implant and allow vessel restoration. Some studies have suggested that the risk of device thrombosis is higher with bioresorbable scaffolds than with metallic stents. Although these scaffolds have gained acceptance and are FDA approved,…
